Jiangsu Hengrui Medicine (SHA:600276) received a drug registration certificate from the Chinese drug administration for abrocitinib sulfate tablets, according to a Shanghai Stock Exchange filing on Wednesday.
The drug is used to treat adult patients with moderate-to-severe atopic dermatitis who have had an inadequate response to topical therapies or other systemic treatments, or who are intolerant to such treatments, the pharmaceutical company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments